BE
BEIGF
BeOne Medicines Ltd.
$21.95
-2.48%
No data for this timeframe.
Vol
SEC Reports3
Recent Activity
Jun 8, 2026
SEC
Board member John Oyler filed a Form 144 to sell 4,940 ADSs (~$1.3M at the prevailing market price) from restricted stoc
144 — Impact 2/10
May 6, 2026
SEC
BeOne Medicines reported Q1 2026 total revenue of $1.51B, a 35% YoY increase, driven by BRUKINSA global sales of $1.1B (
8-K — Impact 8/10
Apr 27, 2026
clinical_trial_readout
T-90d Trial Readout: Tislelizumab (Phase 3)
Trial: Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advan
Apr 14, 2026
SEC
BeOne Medicines filed an 8-K to disclose additional financial information prepared under PRC GAAP in its STAR Annual Rep
8-K — Impact 3/10
Analyst Ratings
3Strong Buy
8Buy
1Hold
0Sell
0Strong Sell
Latest Reports
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
3 SEC filing reports analyzed. Sentiment: 1 bullish, 0 bearish, 0 mixed, 2 neutral. Avg impact: 4.3/10.
NEUTRAL
144
2/10
Board member John Oyler filed a Form 144 to sell 4,940 ADSs (~$1.3M at the prevailing market price)
Jun 8, 2026
BULLISH
8-K
8/10
BeOne Medicines reported Q1 2026 total revenue of $1.51B, a 35% YoY increase, driven by BRUKINSA glo
May 6, 2026
NEUTRAL
8-K
3/10
BeOne Medicines filed an 8-K to disclose additional financial information prepared under PRC GAAP in
Apr 14, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution: 92% buy across 12 analysts — 3 strong buy, 8 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $1.6B | 21.2% | — |
| Next Q 2026-09-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $1.7B | 18.1% | — |
| Current FY 2026-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $6.5B | 21.2% | — |
| Next FY 2027-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $7.4B | 14.6% | — |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 3 | 8 | 1 | 0 | 0 | 92% | |
| May 1, 2026 | 3 | 11 | 1 | 0 | 0 | 93% | |
| Apr 1, 2026 | 3 | 11 | 1 | 0 | 0 | 93% | |
| Mar 1, 2026 | 3 | 11 | 1 | 0 | 0 | 93% | |
| Feb 1, 2026 | 3 | 11 | 1 | 0 | 0 | 93% | |
| Jan 1, 2026 | 3 | 12 | 1 | 0 | 0 | 94% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Apr 27, 2026
clinical_trial_readout
T-90d Trial Readout: Tislelizumab (Phase 3)
Trial: Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies
Sponsor: BeOne Medicines
Phase: P
Apr 13, 2026
clinical_trial_readout
T-90d Trial Readout: Tislelizumab (Phase 3)
Trial: Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies
Sponsor: BeOne Medicines
Phase: P